Hypertension: Overly important but under-controlled

European Journal of Preventive Cardiology

Volumn 24, Issue 3, 2017, Pages 36-43

  van Kleef, Monique E A M ^a   Spiering, Wilko ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Hypertension diagnosis; Hypertension management; Hypertension treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ALCOHOL CONSUMPTION; AORTIC ANEURYSM; ARTICLE; AWARENESS; BLOOD PRESSURE; BODY WEIGHT LOSS; CARDIOMYOPATHY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; EXERCISE; HAZARD RATIO; HEART MUSCLE CONDUCTION DISTURBANCE; HIGH INCOME COUNTRY; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY DENERVATION; LIFESTYLE MODIFICATION; LOW INCOME COUNTRY; META ANALYSIS (TOPIC); MIDDLE INCOME COUNTRY; OFFICE WORKER; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PRESSORECEPTOR REFLEX; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SODIUM INTAKE; TREATMENT REFUSAL; ATTITUDE TO HEALTH; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; DRUG EFFECTS; MEDICATION COMPLIANCE; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 85029326500     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487317709116     Document Type: Article

References (62)

1. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA 2017; 317: 165–182.
2. Global Burden of Disease Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1659–1724.
3. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 2016; 134: 441–450.
4. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378: 1231–1243.
5. van den Berg MJ, van der Graaf Y, de Borst GJ, et al. Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, triglycerides, and apolipoprotein B and cardiovascular risk in patients with manifest arterial disease. Am J Cardiol 2016; 118: 804–810.
6. Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet 2016; 388: 2665–2712.
7. Drouin D, Campbell NR and Kaczorowski J. Implementation of recommendations on hypertension: the Canadian Hypertension Education Program. Can J Cardiol 2006; 22: 595–598.
8. Feldman RD, Campbell NR and Wyard K. Canadian Hypertension Education Program: the evolution of hypertension management guidelines in Canada. Can J Cardiol 2008; 24: 477–481.
9. Schiffrin EL, Campbell NR, Feldman RD, et al. Hypertension in Canada: past, present, and future. Ann Glob Health 2016; 82: 288–299.
10. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757–764.
11. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ (Clin Res Ed) 1985; 291: 97–104.
12. Petruski-Ivleva N, Viera AJ, Shimbo D, et al. Longitudinal patterns of change in systolic blood pressure and incidence of cardiovascular disease: the Atherosclerosis Risk in Communities Study. Hypertension 2016; 67: 1150–1156.
13. Pickering TG, Miller NH, Ogedegbe G, et al. Call to action on use and reimbursement for home blood pressure monitoring: Executive Summary. A joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. J Clin Hypertens 2008; 10: 467–476.
14. Agarwal R, Bills JE, Hecht TJ, et al. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension 2011; 57: 29–38.
15. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–1357.
16. Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens 2010; 24: 779–785.
17. Bloch MJ and Basile JN. UK guidelines call for routine 24-hour ambulatory blood pressure monitoring in all patients to make the diagnosis of hypertension – not ready for prime time in the United States. J Clin Hypertens (Greenwich) 2011; 13: 871–872.
18. Sheridan S, Pignone M and Donahue K. Screening for high blood pressure: a review of the evidence for the U.S. Preventive Services Task Force. Am J Prev Med 2003; 25: 151–158.
19. Leung AA, Nerenberg K, Daskalopoulou SS, et al. Hypertension Canada’s 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2016; 32: 569–588.
20. Pickering TG, Miller NH, Ogedegbe G, et al. Call to action on use and reimbursement for home blood pressure monitoring: Executive Summary. A joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. J Clin Hypertens (Greenwich) 2008; 10: 467–476.
21. Carrera PM and Lambooij MS. Implementation of out-of-office blood pressure monitoring in the Netherlands: from clinical guidelines to patients’ adoption of innovation. Medicine (Baltimore) 2015; 94: e1813.
22. Cohen JB and Cohen DL. Integrating out-of-office blood pressure in the diagnosis and management of hypertension. Curr Cardiol Rep 2016; 18: 112.
23. Rimoldi SF, Scherrer U and Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 2014; 35: 1245–1254.
24. Streeten DH, Anderson GH Jr. and Wagner S. Effect of age on response of secondary hypertension to specific treatment. Am J Hypertens 1990; 3: 360–365.
25. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510–526.
26. Rimoldi SF, Messerli FH, Bangalore S, et al. Resistant hypertension: what the cardiologist needs to know. Eur Heart J 2015; 36: 2686–2695.
27. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled RHEOS pivotal trial. J Am Coll Cardiol 2011; 58: 765–773.
28. Spiering W, Van Der Heyden J, Devireddy C, et al. Lb02.05: Controlling and lowering blood pressure with the mobiushd device: first-in-man results (Calm-Fim Study). J Hypertens 2015; 33(Suppl 1): e86.
29. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889–1916.
30. Mulatero P, Monticone S, Burrello J, et al. Guidelines for primary aldosteronism: uptake by primary care physicians in Europe. J Hypertens 2016; 34: 2253–2257.
31. Graudal NA, Hubeck-Graudal T and Jurgens G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. Cochrane Database Syst Rev 2011; 11: CD004022.
32. Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure – a meta-analysis of randomized controlled trials. Hypertension 2001; 38: 1112–1117.
33. Moore TJ, Vollmer WM, Appel LJ, et al. Effect of dietary patterns on ambulatory blood pressure: results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group. Hypertension 1999; 34: 472–477.
34. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002; 136: 493–503.
35. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42: 878–884.
36. Neutel CI and Campbell N, Canadian Hypertension Study. Changes in lifestyle after hypertension diagnosis in Canada. Can J Cardiol 2008; 24: 199–204.
37. Hinderliter AL, Sherwood A, Craighead LW, et al. The long-term effects of lifestyle change on blood pressure: one-year follow-up of the ENCORE study. Am J Hypertens 2014; 27: 734–741.
38. Jallinoja P, Absetz P, Kuronen R, et al. The dilemma of patient responsibility for lifestyle change: perceptions among primary care physicians and nurses. Scand J Prim Health Care 2007; 25: 244–249.
39. Wood DA, Kotseva K, Connolly S, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008; 371: 1999–2012.
40. Cramer JA. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am J Manag Care 1998; 4: 1563–1568.
41. Peltzer K. Health beliefs and prescription medication compliance among diagnosed hypertension clinic attenders in a rural South African Hospital. Curationis 2004; 27: 15–23.
42. Wetzels GEC, Nelemans P, Schouten JS, et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22: 1849–1855.
43. DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40: 794–811.
44. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34: 2940–2948.
45. Krousel-Wood M, Holt E, Joyce C, et al. Differences in cardiovascular disease risk when antihypertensive medication adherence is assessed by pharmacy fill versus self-report: the Cohort Study of Medication Adherence among Older Adults (CoSMO). J Hypertens 2015; 33: 412–420.
46. Iuga AO and McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy 2014; 7: 35–44.
47. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006; 19: 1190–1196.
48. de Jager RL, de Beus E, Beeftink MA, et al. The impact of medication adherence on the effect of renal denervation – the Sympathy trial. Hypertension 2017; 69: 678–684.
49. Peacock E and Krousel-Wood M. Adherence to antihypertensive therapy. Med Clin N Am 2017; 101: 229.
50. Schroeder K, Fahey T and Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 2004; 164: 722–732.
51. van Dalem J, Krass I and Aslani P. Interventions promoting adherence to cardiovascular medicines. Int J Clin Pharm 2012; 34: 295–311.
52. Conn VS, Ruppar TM, Chase JA, et al. Interventions to improve medication adherence in hypertensive patients: systematic review and meta-analysis. Curr Hypertens Rep 2015; 17: 94.
53. Fletcher BR, Hartmann-Boyce J, Hinton L, et al. The effect of self-monitoring of blood pressure on medication adherence and lifestyle factors: a systematic review and meta-analysis. Am J Hypertens 2015; 28: 1209–1221.
54. Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002; 24: 302–316.
55. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713–719.
56. Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013; 310: 918–929.
57. Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000; 35: 539–543.
58. Lewington S, Clarke R, Qizilbash N, et al.; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.
59. Cushman WC, Evans GW, Byington RP, et al.; the Accord Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575–1585.
60. Wright JT Jr., Williamson JD, Whelton PK, et al.; the SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103–2116.
61. Kjeldsen SE, Lund-Johansen P, Nilsson PM, et al. Unattended blood pressure measurements in the Systolic Blood Pressure Intervention Trial: implications for entry and achieved blood pressure values compared with other trials. Hypertension 2016; 67: 808–812.
62. Filipovsky J, Seidlerova J, Kratochvil Z, et al. Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients. Blood Pressure 2016; 25: 228–234.